Limitations
PD, Δ9-THC
ADVERSE EFFECTS
This study has limitations. First, a single dose of Δ9-THC (20 mg) and CBD (640 mg) was administered, and a CBD only condition was lacking. Future studies comparing multiple doses and ratios of Δ9-THC and CBD are needed to determine the generality of the observed associations, as well as the dose threshold for clinically significant alterations in PD outcomes. Second, the outcomes for Δ9-THC and Δ9-THC + CBD were assessed in the context of an oral CYP cocktail. Although no adverse effects were noted when the CYP cocktail was administered after the placebo brownie, the CYP cocktail may have contributed to the behavioral outcomes observed during the active cannabis conditions. Third, although the study included both males and females, the sample size of the present study was not powered to detect potential sex differences, which have been shown to influence acute cannabis effects.